Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03036384
Other study ID # NB076201627436
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2016
Est. completion date November 2016

Study information

Verified date April 2020
Source Centre Hospitalier Universitaire Saint Pierre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hyperbaric bupivacaine 0.5% associated with opioids is the local anesthetic the most commonly used for spinal injection in cesarean section. Nevertheless, its use often results in a long duration of motor nerve block and a haemodynamical instability. Recently developped, the Prilocaine, with its new 2% hyperbaric formulation, seems to offer a good alternative for hyperbaric bupivicaine. A first study has determined the ED95 of hyperbaric prilocaine 2% for intrathecal anesthesia in scheduled cesarean delivery. As opioid adjuvants potentiate the effect of the local anesthetics while decreasing their dose-related side effects, the aim of this study is to determine the ED95 of hyperbaric prilocaine 2% with sufentanyl for scheduled cesarean delivery under spinal anesthesia,by using the Continual Reassessment Method (CRM)


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date November 2016
Est. primary completion date November 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- American Society of Anesthesiologists physical status (ASA) < III

- Age 18-40 year

- Body Weight <100 kg

- Height between 155 and 175 cm

- Gestational age>37 SA

- Elective cesarean delivery

- Singleton pregnancy

- Non complicated pregnancy

- Signed informed consent obtained prior to any study specific assessments and procedures

Exclusion Criteria:

- Twin pregnancy

- History of 2 cesarean section or more

- Diabetes and gestational diabetes

- Placenta praevia

- Congenital foetal abnormality

- Patient in labour

- Membrane rupture

- Known allergy to local anaesthetics

- Disagreement of the patient

- Pregnancy-induced hypertension

- Pre eclampsia and eclampsia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HB Prilocaine 2% (varying dose)
Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
HB Prilocaine 2%
The dose of 45mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 2.5µg of sufentanyl
Sufentanil
2.5µg sufentanyl
Morphine
100 µg Morphine

Locations

Country Name City State
Belgium University Hospital Saint-Pierre, Université Libre de Bruxelles (ULB) Brussels Capital Region

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Saint Pierre

Country where clinical trial is conducted

Belgium, 

References & Publications (2)

Camponovo C, Fanelli A, Ghisi D, Cristina D, Fanelli G. A prospective, double-blinded, randomized, clinical trial comparing the efficacy of 40 mg and 60 mg hyperbaric 2% prilocaine versus 60 mg plain 2% prilocaine for intrathecal anesthesia in ambulatory surgery. Anesth Analg. 2010 Aug;111(2):568-72. doi: 10.1213/ANE.0b013e3181e30bb8. Epub 2010 Jun 7. — View Citation

Gupta PK, Chevret S, Zohar S, Hopkins PM. What is the ED95 of prilocaine for femoral nerve block using ultrasound? Br J Anaesth. 2013 May;110(5):831-6. doi: 10.1093/bja/aes503. Epub 2013 Feb 7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Success of Anesthesia The nerve blockade will be considered as success when a bilateral T4 level will reach in 15 minutes after intrathecal injection without additional epidural injection needed within 45 minutes peri-operative ; no pain at the skin incision, no pain during 45 minutes after the skin incision during surgery (average 1 hour)
Secondary Sensitive Block Duration Level of Sensory block assessed as loss of sensation to cold, every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1). Until complete release of sensory block (T12-S1) (average 4 hours)
Secondary Sensitive Block at End of Surgery Level of Sensory block assessed as loss of sensation to cold, every 2 minutes after spinal anesthesia during 15 minutes, then every 5 minutes until the end of surgery, thereafter, once 30 minutes until total regression of sensory block (T12-S1). For this study, dermatome levels are depicted on a scale ranging from 1 to 18. (1 to 12 = T1-T12 thoracic levels; 13 to 17 = L1-L5 lumbar levels; 18 = S1 sacral level) Until complete release of sensory block (T12-S1) (average 4 hours)
Secondary Motor Block Duration Bromage scale (1 = no motor block; 2 = hip blocked; 3 = hip and knee blocked; and 4 = hip, knee, and ankle blocked) was used to evaluate the motor block every 15 minutes after spinal anaesthesia (T0) and until the end of surgery. Duration was defined from the time of the spinal injection until Bromage scale = 1. Until complete release of motor block (Bromage scale = 1; average 4 hours)
Secondary Bromage Motor Block Level at End of Surgery Bromage scale (1 = no motor block; 2 = hip blocked; 3 = hip and knee blocked; and 4 = hip, knee, and ankle blocked) was used to evaluate the motor block every 15 min after spinal anaesthesia (T0) and until the end of surgery. Until complete release of motor block (average 4 hours)
Secondary Newborn Apgar Score Newborn Apgar score assessed at 1, 5, 10 minutes after baby extraction. The Apgar score is determined by evaluating the newborn baby on five simple criteria on a scale from 0 to 2, then summing up the five values thus obtained. The overall resulting score ranges from 0 to 10 ( 0-3 : severely depressed, 4-6 : Moderately depressed and 7-10 : Excellent condition).
The five criteria are summarized using words chosen to form an abbreviation (Appearance, Pulse, Grimace, Activity, Respiration).
up to 10 minutes after baby extraction
Secondary Newborn Methemoglobinemia (MetHb) Newborn Methemoglobinemia (MetHb) will be assessed at delivery by cordal blood sample, as a routine control, and expressed as a percentage of total hemoglobinemia. average 1 hour
Secondary Number of Participants Needing Vasopressors Arterial blood pressure will be measured at every 2.5 minute during surgery, then at every 20 minutes in the PACU (Post Anesthesia Care Unit). Vasopressors were given for patients with low blood pressure.
A low blood pressure is defined as a blood pressure lower than 20% or more than the basal blood pressure (Systolic blood pressure before spinal anesthesia).
during surgery (average 1 hour)
Secondary Number of Participants With Transient Neurologic Symptoms (TNS) TNS are defined as pain and/or dysesthesia occurred after complete release of sensory block at the gluteal level, at the thighs and at the legs. At Day 0, Day 1, Day 3 and Day 5 up to 5 Days
Secondary Number of Participants With Nausea or Vomiting from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated) up to 24 hours after surgery
Secondary Number of Participants With Pruritus from 15 minutes after spinal anesthesia and every 4 hours for 24 hours (score 0=no symptoms; 1=symptoms with no treatment necessary; 2=symptoms present and treated) Up to 24 hours after surgery
Secondary Number of Participants With Urinary Retention All parturients will be questioned for urinary retention (yes or no) Up to 24 hours after surgery
Secondary Number of Participants With Dizziness All parturients will be questioned for dizziness (yes or no) Up to 24 hours after surgery
Secondary Number of Satisfied Participants Maternal satisfaction (yes or no) will be assessed 1 hour after surgery in the PACU (Post Anesthesia Care Unit) up to 1 hour after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03955263 - Malaria In Pregnancy in Central India
Not yet recruiting NCT04457947 - Exploring Aromatherapy Intervention in Acute Care
Active, not recruiting NCT01397318 - Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight N/A
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
Not yet recruiting NCT00931099 - Fetal Outcome of Sleep Disordered Breathing During Pregnancy N/A
Recruiting NCT00751569 - microRNA Profile in Umbilical Cord Blood NK Cells N/A
Completed NCT06111716 - Mindfulness in Childbirth Preparation Education Process N/A
Completed NCT05729191 - Evaluation of the Acceptance of the Anti-COVID-19 Vaccine Offer Among Pregnant Women
Completed NCT01687634 - Home Visiting for Low Income, Pregnant Women N/A
Recruiting NCT05446571 - Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir Phase 3
Not yet recruiting NCT03651934 - Verification of Correlation Between Genetic Testing of Nutritional Metabolism and Clinical Biochemical Indicators N/A
Completed NCT02904473 - Goals for Reaching Optimum Wellness (GROWell) N/A
Completed NCT03538106 - Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes
Recruiting NCT01246765 - National Pregnancy Registry for Psychiatric Medications
Completed NCT00553228 - Pertussis Maternal Immunization Study Phase 2/Phase 3
Recruiting NCT05916534 - We Care About Brooklyn - A Digital Behavioral Intervention to Optimize Engagement in Maternal Healthcare N/A
Completed NCT04264910 - CALM Pregnancy: Feasibility of Calm for Pregnant Women N/A
Completed NCT04494581 - GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
Recruiting NCT05349279 - Qatar PREgnancy Covid-19 OUtcome Study
Withdrawn NCT04354441 - Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women Phase 2